The Company has determined that it is not able to meet the
Although the Company remains confident in its ability to complete the 2023 Filings, it requires an extension and has therefore applied for an MCTO. In particular, the Company has prepared a realistic timetable with specific tasks to be completed on a daily basis. The Company will use its best efforts to complete the process within this timeline. The Company anticipates that, subject to current conditions remaining the same, it will require approximately three additional weeks to complete the process of preparing the 2023 Filings and in any event will use its best efforts to complete the process within the next two months.
The Company intends to satisfy the provisions of the alternative information guidelines set out in Sections 9 and 10 of NP 12-203 so long as the 2023 Filings are outstanding. The Company is not subject to any insolvency proceedings.
About
In
Additional information about the Company is available at www.rammpharma.com.
For further information, please contact:
Executive Assistant
+598 2513 99 58
info@rammpharma.com
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the ability of the Company to file the 2023 Filings by the timelines set out in the release, the ability of the Company to obtain a management cease trade order and the ability of the Company to be in compliance of NP 12-203. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements including, among other things, the risks that the Company will not be able to file the Fillings in the required timeframe, or at all, that the Company will not be able to obtain a management cease trade order, that the Company will not be able to comply with NP 12-203, and that the Company's products and plans will vary significantly as a result. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Source:
2023 GlobeNewswire, Inc., source